Keros Therapeutics Inc

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

KROS$9.17-2.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	YEAR ENDED DECEMBER 31,
	2023	2022	2021
REVENUE:
Service and other revenue	$151	$—	$—
License revenue	—	—	20,100
Total revenue	151	—	20,100
OPERATING EXPENSES:
Research and development	(135,258)	(87,265)	(55,143)
General and administrative	(34,834)	(27,525)	(21,330)
Total operating expenses	(170,092)	(114,790)	(76,473)
LOSS FROM OPERATIONS	(169,941)	(114,790)	(56,373)
OTHER INCOME (EXPENSE), NET:
Interest expense, net	—	(1)	(4)
Research and development incentive income	2,400	7,081	—
Dividend income	14,755	3,644	27
Other income (expense), net	(206)	(613)	(383)
Total other income (expense), net	16,949	10,111	(360)
Loss before income taxes	(152,992)	(104,679)	(56,733)
Income tax provision	—	—	(2,011)
Net loss	$(152,992)	$(104,679)	$(58,744)
Net loss attributable to common stockholders—basic and diluted	$(152,992)	$(104,679)	$(58,744)
Net loss per share attributable to common stockholders—basic and diluted	$(5.20)	$(4.15)	$(2.52)
Weighted-average common stock outstanding—basic and diluted	29,447,119	25,241,030	23,333,914

Consolidated Statements of Stockholders’ Equity

COMMON STOCK$0.0001 PAR VALUE · ADDITIONALPAID-INCAPITAL · ACCUMULATEDDEFICIT · TOTAL STOCKHOLDERS’ EQUITY
SHARES · AMOUNT
BALANCE, January 1, 2021	23,192,866	$2	$326,730	$(65,011)	$261,721
Issuance of common stock under the ATM agreement, net of commissions and offering cost of $475	520,000	—	28,096	—	28,096
Exercise of common stock options	261,968	—	379	—	379
Stock-based compensation	—	—	11,722	—	11,722
Net loss	—	—	—	(58,744)	(58,744)
BALANCE, December 31, 2021	23,974,834	$2	$366,927	$(123,755)	$243,174
Issuance of common stock under the ATM agreement, net of commissions and offering cost of $1,971	3,410,384	—	119,428	—	119,428
Exercise of common stock options	158,235	—	818	—	818
Stock-based compensation	—	—	18,682	—	18,682
Net loss	—	—	—	(104,679)	(104,679)
BALANCE, December 31, 2022	27,543,453	$2	$505,855	$(228,434)	$277,423
Issuance of common stock under the ATM agreement, net of commissions and offering cost of $2,708	4,061,606	1	175,793	—	175,794
Exercise of common stock options	236,025	—	3,225	—	3,225
Stock-based compensation	—	—	28,763	—	28,763
Net loss	—	—	—	(152,992)	(152,992)
BALANCE, December 31, 2023	31,841,084	$3	$713,636	$(381,426)	$332,213

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.